Chengzhi Lu

机构：Palo Alto University, Tianjin First Center Hospital, Tianjin Medical University, Stanford University · ORCID：0000-0001-9609-9815

发表论文 27 篇 · 总被引 261 次 · h-index 10

代表论文

• A ROS-Responsive Simvastatin Nano-Prodrug and its Fibronectin-Targeted Co-Delivery System for Atherosclerosis Treatment (2022 · ACS Applied Materials & Interfaces · 被引 52)
• Targeting mitochondria-inflammation circle by renal denervation reduces atheroprone endothelial phenotypes and atherosclerosis (2021 · Redox Biology · 被引 49)
• Involvement of non‑coding RNAs in the pathogenesis of myocardial ischemia/reperfusion injury (Review) (2021 · International Journal of Molecular Medicine · 被引 30)
• Maslinic Acid Attenuates Ischemia/Reperfusion Injury-Induced Myocardial Inflammation and Apoptosis by Regulating HMGB1-TLR4 Axis (2021 · Frontiers in Cardiovascular Medicine · 被引 20)
• Galectin-3 inhibition attenuates doxorubicin-induced cardiac dysfunction by upregulating the expression of peroxiredoxin-4 (2020 · Canadian Journal of Physiology and Pharmacology · 被引 20)
• [The effect of catheter based renal synthetic denervation on renin-angiotensin-aldosterone system in patients with resistant hypertension]. (2013 · PubMed · 被引 20)